Kali-Extracts, Inc. announced an update from CEO Frederick Ferri on the company’s continuing Cannabis Extract Biopharmaceutical developments scheduled on October 7, 2019. The last Cannabis Extract Biopharmaceutical developments update was issued over one month ago. The company has made some substantial strides forward since that time and looks forward to sharing the progress with shareholders. The update will include the latest information on the company’s CBD formulation for treating symptoms associated with Chronic Obstructive Pulmonary Disease (COPD) and other similar respiratory conditions. The formulation for the treatment of symptoms associated with COPD and other similar respiratory conditions has been derived from the company’s patented cannabis extraction process. In conjunction with the research already conducted and the next phase of research now moving forward, KALY recently filed for a new patent application specifically on its formulation for symptoms associated with COPD and other similar respiratory conditions. KALY also filed for a trademark on the name RespRx as the brand name for its CBD formulation to treat the symptoms associated with COPD and other similar respiratory conditions.